Why Clarivate Stock Is Skyrocketing Today

Core Viewpoint - Clarivate's stock surged by 31.4% following the release of its fourth-quarter earnings report, which exceeded market expectations in both sales and earnings [1][2]. Financial Performance - Clarivate reported non-GAAP earnings of $0.20 per share on sales of $617 million, surpassing analyst estimates of $0.16 per share on sales of $604.8 million [5]. - Year-over-year revenue declined by approximately 7%, but the decrease was less severe than anticipated [5]. - Subscription revenues slightly decreased to $405.8 million from $407 million, but showed a 1% increase on an organic basis [5]. Future Outlook - The company is targeting a 10% growth in free cash flow for the current year and expects annual contract value growth between 2% and 3% [6]. - Recurring organic revenue is projected to increase by 1% to 2% [6]. Strategic Moves - Clarivate is in active discussions to sell its life sciences and healthcare business, aiming to use the proceeds to reduce debt and enhance its balance sheet [7]. - The company plans to focus on expansion in academia-and-government and intellectual-property sectors following the potential sale [7].